G. Masilamoni

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Gunasingh Jeyaraj Masilamoni, Gunasingh Masilamoni, Gunasingh J. Masilamoni, G. J. Masilamoni, Gunasingh J Masilamoni
Publication record
20 papers · 577 citations · H-index 12

PAPERS

Dysfunction of motor cortices in Parkinson’s disease
202418 citationsauthor #6
Phosphodiesterase 9 inhibition prolongs the antiparkinsonian action of l-DOPA in parkinsonian non-human primates.
20223 citationsauthor #1
Cortical Serotonergic and Catecholaminergic Denervation in MPTP-Treated Parkinsonian Monkeys.
202112 citationsauthor #1
Sexually dimorphic responses to MPTP found in microglia, inflammation and gut microbiota in a progressive monkey model of Parkinson’s disease
20201 citationsauthor #2
Microglia, inflammation and gut microbiota responses in a progressive monkey model of Parkinson's disease: A case series.
202044 citationsauthor #2
Group I metabotropic glutamate receptors in the primate motor thalamus: subsynaptic association with cortical and sub-cortical glutamatergic afferents
20195 citationsauthor #1
Metabotropic glutamate receptors: targets for neuroprotective therapies in Parkinson disease.
201837 citationsauthor #1
Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson’s disease
201870 citationsauthor #1
Neuroprotective Properties of Glutamate Metabotropic Glutamate Receptors in Parkinson’s Disease and Other Brain Disorders
20172 citationsauthor #1
Reduced noradrenergic innervation of ventral midbrain dopaminergic cell groups and the subthalamic nucleus in MPTP-treated parkinsonian monkeys.
201732 citationsauthor #1
Lack of Antiparkinsonian Effects of Systemic Injections of the Specific T-Type Calcium Channel Blocker ML218 in MPTP-Treated Monkeys.
20169 citationsauthor #4
Effects of a novel phosphodiesterase 10A inhibitor in non-human primates: A therapeutic approach for schizophrenia with improved side effect profile.
20169 citationsauthor #1
Phosphodiesterase 10A inhibitor MP-10 effects in primates: comparison with risperidone and mechanistic implications.
201421 citationsauthor #2
Role of Protein Aggregation and Interactions between α-Synuclein and Calbindin in Parkinson's Disease
20130 citationsauthor #5
Extrastriatal D2-like receptors modulate basal ganglia pathways in normal and Parkinsonian monkeys.
201232 citationsauthor #3
Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.
2011106 citationsauthor #1
Sequestration of Toxic Oligomers by HspB1 as a Cytoprotective Mechanism
201198 citationsauthor #2
F-FECNT : Validation as PET dopamine transporter ligand in parkinsonism
20104 citationsauthor #1
(18)F-FECNT: validation as PET dopamine transporter ligand in parkinsonism.
201041 citationsauthor #1
Lethal and sub-lethal effects of chlorination on green mussel Perna viridis in the context of biofouling control in a power plant cooling water system.
200236 citationsauthor #1

TIMELINE

2002 36 citations

2010 45 citations

2011 204 citations

2012 32 citations

2013 0 citations

2014 21 citations

2016 18 citations

2017 34 citations

2018 107 citations

2019 5 citations

2020 45 citations

2021 12 citations

2022 3 citations

2024 18 citations

G. Masilamoni

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT